Recently, targeting the PD-1/PD-L1 immune checkpoint pathway has proved to improve adults patients’ survival, but with less toxicity than conventional treatments, possibly stimulating the anti-tumor immunity by activating the patients’ own immune system [7]. Here, CD274 is linked to neoplasm.